公开(公告)号：US20170100368A1

公开(公告)日：2017-04-13

申请号：US15314200

申请日：2015-05-28

申请人： David COX ,  Alton KRAMER ,  Sharon MCGONIGLE ,  Jiayi WU ,  Eisai R&D Management Co., Ltd.

发明人： David COX ,  Alton KREMER ,  Sharon MCGONIGLE ,  Jiayi WU

IPC分类号： A61K31/357 ,  A61K31/555 ,  A61K31/519

CPC分类号： A61K31/357 ,  A61K31/519 ,  A61K31/555 ,  A61K45/06 ,  A61K2300/00

摘要： The invention features methods for treating cancer in a patient in need thereof by administering eribulin, in combination with one or more PARP inhibitors, and, optionally, a platinum-based antineoplastic drug, and kits therefor. The invention is based in part on the observation that combinations of eribulin mesylate, a PARP inhibitor (e.g., E7449), and, optionally, a platinum-based antineo-plastic drug (e.g., carboplatin), show improved (e.g., synergistic) antitumor effects. Therefore, the present invention features methods of preventing and treating cancer (e.g., homologous recombination (HR)-deficient cancer by the use of combinations of eribulin (e.g., eribulin mesylate) and one or more PARP inhibitors (e.g., E7449 or a pharmaceutically acceptable salt thereof (e.g., the tartrate salt), optionally in combination with a platinum-based antineoplastic drug (e.g., carboplatin).